The 2025 Emergency Approach to Acute Pulmonary Edema
The 2025 Emergency Approach to Acute Pulmonary Edema
Sources:
• Cureus. Published September 14, 2025.
• J Clin Med. Comparison of Guidelines for Acute Heart Failure. Published 2025.
1. Definition and Urgency
• Acute pulmonary edema (APE) is a hyper-acute emergency presentation of alveolar flooding.
• The most common cause is cardiogenic due to acute left ventricular failure, often triggered by acute coronary syndromes (ACS) or hypertensive crisis.
• Patients may present with severe dyspnea, hypoxemia, agitation, and diffuse crackles.
• Blood pressure may be high, normal, or low, and the management must adapt accordingly.
2. Causes of Acute Pulmonary Edema
• Cardiogenic (most common):
• Acute coronary syndromes (STEMI/NSTEMI).
• Hypertensive emergency (SCAPE).
• Acute valvular regurgitation (e.g., mitral, aortic).
• Arrhythmias (AF with rapid ventricular response, VT).
• Acute decompensated chronic heart failure.
• Non-cardiogenic:
• ARDS, sepsis.
• NPE (Neurogenic Pulmonary Edema): occurs after SAH, ICH, massive ischemic stroke with raised ICP, or seizures.
• Toxins/drugs (opioids, salicylates, inhaled gases).
• TRALI (transfusion-related acute lung injury).
• HAPE (high-altitude pulmonary edema).
• Post-obstructive pulmonary edema (after relief of acute upper airway obstruction).
• Pancreatitis.
• Renal & Hepatic failure / fluid overload:
* Renal failure is a frequent contributor (especially ESRD patients on dialysis) → fluid overload → APE.
* Usually classified as exacerbation of HF / cardiogenic-like because it is related to volume/pressure overload.
Cardiogenic causes remain far more common than non-cardiogenic ones, while renal failure with fluid overload is a frequent contributing factor among the latter. In emergency and cardiology wards most cases are cardiogenic, whereas in intensive care units non-cardiogenic causes such as ARDS and sepsis may account for a larger proportion.
3. Initial ED Workup (parallel with stabilization):
• 12-lead ECG → detect ischemia, infarction, arrhythmia.
• High-sensitivity Troponin → confirm/exclude ACS, prognostic value.
• BNP/NT-proBNP:
• Elevated in cardiogenic pulmonary edema:
* BNP >500 pg/mL
* NT-proBNP >1000 pg/mL
• Very low levels (<100) make a cardiac cause unlikely.
• Always interpret in the context of age, renal function, obesity, and comorbidities.
• Chest X-ray and PoCUS → confirm pulmonary congestion, assess heart and IVC.
• Basic labs → renal function, electrolytes, ABG if severe hypoxemia.
4. Immediate Stabilization (Airway and Oxygenation)
• NIV (Non-Invasive Ventilation: CPAP/BiPAP) is first-line if hypoxemic or in respiratory distress.
• Improves oxygenation, reduces preload/afterload, prevents intubation.
• Initiate immediately unless contraindicated.
5. Rapid Bedside Assessment
• PoCUS (Point-of-Care Ultrasound): portable handheld or laptop-sized ultrasound.
• Lungs: B-lines = pulmonary edema.
• Heart: LV systolic function, valvular status.
• IVC: volume status and venous congestion.
• Complements echocardiography, which remains the gold standard.
• Introduced in the 1990s, widely adopted after 2000; now standard in high-income countries, increasingly available in resource-limited settings.
• BNP/NT-proBNP:
• Diagnostic: BNP >500 pg/mL or NT-proBNP >1000 pg/mL suggests cardiogenic cause; <100 excludes it.
• Prognostic: higher levels = worse outcomes.
• Decongestion check: falling levels before discharge support safe transition.
6. Vasodilator Therapy
• Nitroglycerin (IV): cornerstone when blood pressure is elevated.
• Hypertensive APE / SCAPE (SBP ≥160 mmHg):
• Bolus: 600–1000 µg IV over 1–2 min.
• Infusion: start 100–200 µg/min, titrate up to ~400 µg/min if tolerated.
• Normotensive APE (SBP 110–140 mmHg):
• Optional low-dose infusion (20–40 µg/min) if congestion is significant and BP stable.
• Hypotension (SBP <100 mmHg or shock):
• Avoid nitroglycerin; manage with vasopressors/inotropes and cautious fluids.
7. Role of Loop Diuretics
• Not first-line in hypertensive flash edema (SCAPE).
• Normotensive APE: IV furosemide is the pharmacologic cornerstone.
• Timing: after stabilization of oxygenation and BP (≈15–30 min).
• Dosing:
• 40–80 mg IV initially.
• If on chronic diuretics → 1–2× home dose IV.
• Goal: gradual decongestion and sustained relief of symptoms.
8. Non-Cardiogenic Pulmonary Edema (NCPE) – Management
• Treat the underlying cause (infection, neurologic insult, altitude, toxins).
• Provide oxygen therapy.
• Use cautious fluids; add vasopressors if indicated.
• Apply lung-protective ventilation if intubated.
• Utilize PoCUS (complements echocardiography in ER) to help differentiate NCPE from cardiogenic forms.
Key Takeaways (2025 Evidence)
1. Always rule out ACS with ECG + Troponin.
2. NIV + high-dose nitroglycerin = lifesaving in hypertensive APE.
3. Loop diuretics = cornerstone in normotensive APE; delayed in SCAPE.
4. PoCUS = rapid bedside tool; echo remains gold standard.
5. BNP/NT-proBNP = diagnostic, prognostic, and discharge guidance.
6. Avoid nitro in hypotension; support with vasopressors/inotropes.
7. Cardiogenic causes remain far more common; renal failure with fluid overload is a frequent contributor among non-cardiogenic.
8. Early, aggressive therapy reduces intubation, ICU stay, and mortality.
Sources:
https://www.cureus.com/articles/381557
